The various manifestations of atherosclerotic cardiovascular disease are the major cause of mortality in patients with type 2 diabetes. Learn more about management and new therapies with proven cardiovascular safety and benefits.
Cardiovascular protection in the treatment of type 2 diabetes
Printable Q&A for Offline SubmissionQuiz-summary
0 of 10 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- Answered
- Review
- Question 1 of 10
1. Question
1. T2DM patients experience an up to ___% increased risk of cardiovascular-related death:
- Question 2 of 10
2. Question
2. CVOT assessment of new glucose-lowering drugs must include a 3P-MACE including ________ prior to registration:
- Question 3 of 10
3. Question
3. Regulations state that if for the risk of MACE, the upper limit of the 95% confidence interval of the estimated risk is ___, the drug cannot be approved:
- Question 4 of 10
4. Question
4. Of the DPP-4 inhibitors, which is/are associated with increased risk of hospitalisation for HF?
- Question 5 of 10
5. Question
5. Which statement is incorrect? Mechanisms through which GLP-1 RAs affect glucose control include:
- Question 6 of 10
6. Question
6. Of the GLP-1 RAs, liraglutide, semaglutide and exenatide are the preferred agents for reduction of ASCVD risk:
- Question 7 of 10
7. Question
7. GLP-1 RAs should be avoided in patients with a history of:
- Question 8 of 10
8. Question
8. All SGLT-2 inhibitors have demonstrated benefit for MACE in T2DM patients with HF and CKD:
- Question 9 of 10
9. Question
9. Which of these SGLT-2 inhibitors is/are preferred for use in the T2DM patient with ASCVD?
- Question 10 of 10
10. Question
10. Which statement is incorrect? Early results of some studies of combination therapy with SGLT-2 inhibitors and GLP-1 RAs have shown positive complementary effects on:
Do you like this? Share with a colleague
[DISPLAY_ULTIMATE_SOCIAL_ICONS]